Article Information
History
- January 10, 2019.
Article Versions
- You are currently viewing Version 1 of this article (January 10, 2019 - 13:34).
- Version 2 (August 9, 2019 - 06:44).
- View Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Olga Pernía1,2,*,
- Ana Sastre-Perona3,*,
- Carlos Rodriguez-Antolín1,2,
- Alvaro García-Guede1,2,
- María Palomares-Bralo4,5,
- Rocío Rosas1,2,
- Darío Sanchez-Cabrero2,
- Carmen Rodriguez1,2,
- Rubén Martín-Arenas4,5,
- Verónica Pulido1,2,
- Javier de Castro2,
- Pilar Santisteban3,6,
- Olga Vera1,2,+ and
- Inmaculada Ibáñez de Cáceres1,2,+
- 1Laboratorio de Epigenétic, INGEMM, Hospital La PAZ. Madrid.
- 2Terapias Experimentales y Biomarcadores en Cáncer. N33. IdiPAZ. Madrid.
- 3Instituto de Investigaciones Biomedicas CSIC/UAM. Madrid.
- 4Ciber de Enfermedades Raras (CIBERER). Instituto de Salud Carlos III (ISCIII), Madrid.
- 5Laboratorio de Genómica Estructural y Funcional, INGEMM. IdiPAZ. Madrid.
- 6Ciber de Cáncer (CIBERONC) Instituto de Salud Carlos III (ISCIII), Madrid.
- ↵+Corresponding authors:
Inmaculada Ibañez de Caceres E-mail: inma.ibanezca{at}salud.madrid.org, Olga Vera Puente E-mail: olga.verapuente{at}moffitt.org, Cancer Epigenetics Laboratory, INGEMM Biomarkers and Experimental Therapeutics in Cancer, IdiPAZ, Paseo de la Castellana 261, 28046 Madrid, Spain, Phone +34-91-2071010-248, Fax +34-91-2071010
↵* Both authors contributed equally to this work.